SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02496455

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section

The purpose of this study to determine the association between postoperative pain after cesarean section and several single nucleotide polymorphisms in SCN9A sodium channels gene.

NCT02496455 Pain, Postoperative Pregnancy
MeSH:Pain, Postoperative

2 Interventions

Name: cesarean section

Description: Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
Type: Procedure

Name: Opioid Tramadol

Description: Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
Type: Drug

Primary Outcomes

Description: The pain will be evaluated with the visual analog scale

Measure: Pain

Time: up to postoperative 24 hours

Secondary Outcomes

Description: The total amount of the tramadol administered to the patient will be recorded

Measure: Opioid consumption

Time: Up to postoperative 24 hours
Time Perspective: Prospective

Cohort

There are 3 SNPs

SNPs

1 rs10930214

The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section.

2 rs6746030

The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section.

3 rs7604448

The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section.


HPO Nodes